Venlafaxine and Vivid Dreaming

Zullino, Daniele; Riquier, Françoise

doi:10.4088/jcp.v61n0810a

Cited by 13 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Venlafaxine and its metabolite, desvenlafaxine , also tend to modify the dream content, with a large increase of “abnormal dreams” reported in desvenlafaxine withdrawal in depressed patients ( 67 ). With venlafaxine, an emergence of particularly realistic nightmares is observed ( 68 ) as well as episodes of RBD ( 69 ).…”

Section: Effects Of Antidepressants On Dream Recallmentioning

confidence: 99%

Dreams, Sleep, and Psychotropic Drugs

Nicolas

Ruby

2020

Front. Neurol.

View full text Add to dashboard Cite

Over the past 60 years, the impact of psychotropic drugs on dream recall and content has been scarcely explored. A review of the few existing experimental results on the topic leads us to the following conclusions. For antidepressant drugs, in the great majority, they reduce dream recall frequency (DRF), and the improvement of depressive symptoms is associated with an increase of positive emotion in dream content. For sedative psychotropic drugs, their improvement of sleep quality is associated with a reduction of DRF, but the effect on dream content is less clear. Few occurrences of nightmare frequency increase have been reported, with intake of molecules disturbing sleep or with the withdrawal of some psychotropic drugs. Importantly, the impact of psychotropic drugs on rapid eye movement (REM) sleep does not explain DRF modulations. The reduction of intra-sleep awakenings seems to be the parameter explaining best the modulation of DRF by psychotropic drugs. Indeed, molecules that improve sleep continuity by reducing intra-sleep awakenings also reduce the frequency of dream recall, which is coherent with the "arousal-retrieval model" stating that nighttime awakenings enable dreams to be encoded into long-term memory and therefore facilitate dream recall. DRF is nonetheless influenced by several other factors (e.g., interest in dreams, the method of awakening, and personality traits), which may explain a large part of the variability of results observed and cited in this article.

show abstract

Section: Effects Of Antidepressants On Dream Recallmentioning

confidence: 99%

Dreams, Sleep, and Psychotropic Drugs

Nicolas

Ruby

2020

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…Clomipramine almost completely blocks rapid eye movement sleep [56]. Venlafaxine can cause nightmares due to suppression of rapid eye movement sleep, possibly by indirect stimulation of 5‐hydroxytryptamine type 2 receptors [57]. Selective serotonin reuptake inhibitors increase wakefulness, decrease total sleep time and sleep efficiency and suppress rapid eye movement [58,59].…”

Section: Antidepressantsmentioning

confidence: 99%

Sleep disruption in critically ill patients – pharmacological considerations

2004

View full text Add to dashboard Cite

Summary Sleep disturbances are common in critically ill patients and contribute to morbidity. Environmental factors, patient care activities and acute illness are all potential causes of disrupted sleep. Additionally, it is important to consider drug therapy as a contributing factor to this adverse experience, which patients perceive as particularly stressful. Sedative and analgesic combinations used to facilitate mechanical ventilation are among the most sleep disruptive drugs. Cardiovascular, gastric protection, anti‐asthma, anti‐infective, antidepressant and anticonvulsant drugs have also been reported to cause a variety of sleep disorders. Withdrawal reactions to prescribed and occasionally recreational drugs should also be considered as possible triggers for sleep disruption. Tricyclic antidepressants and benzodiazepines are commonly prescribed in the treatment of sleep disorders, but have problems with decreasing slow wave and rapid eye movement sleep phases. Newer non‐benzodiazepine hypnotics offer little practical advantage. Melatonin and atypical antipsychotics require further investigation before their routine use can be recommended.

show abstract

“…16 Smokers may report an increase of remembered dreams during nicotine withdrawal, but this has been suggested to be due to more frequent awakenings. 16 Like venlafaxine, another antidepressant drug which has serotonergic and noradrenergic properties, and at higher doses becomes dopaminergic, 17 there have been reports of vivid dreaming and nightmares associated with bupropion treatment. 18,19 However, bupropion or smoking cessation has not been related to somnambulism until now.…”

Section: Introductionmentioning

confidence: 99%

Bupropion‐induced somnambulism

2003

View full text Add to dashboard Cite

Whereas there are some case reports of bupropion-induced vivid dreaming and nightmares, until now it has not been associated with somnambulism. A case is reported of a patient treated with bupropion as a smoking cessation medication, who developed somnambulism during nicotine withdrawal. Furthermore, the sleepwalking episodes were associated with eating behaviour. Amnesia was reported for all episodes. As, on one hand,bupropion is a noradrenergic and dopaminergic drug and nicotine withdrawal, on the other hand, is associated with alterations in monoaminergic functions, an interaction at the level of these neurotransmitters is suggested as the underlying mechanism.

show abstract

Venlafaxine and Vivid Dreaming

Cited by 13 publications

References 6 publications

Dreams, Sleep, and Psychotropic Drugs

Dreams, Sleep, and Psychotropic Drugs

Sleep disruption in critically ill patients – pharmacological considerations

Bupropion‐induced somnambulism

Contact Info

Product

Resources

About